Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Biblioteca de Periódicos Eletrônicos
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Catálogo online SWB
  • Biblioteca Virtual de Biologia (vifabio)
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Is There Any Cause for Concern in Patients Who Have Their First Helicobacter Like Organism Test Positive?

Syed Nouman Mohsin

Aim: To assess the existing first line triple therapy in patients for possible resistance.
Materials and Methods: Retrospective assessment of all patients who had their Helicobacter pylori positive with biopsies taken for various reasons during gastroscopy followed by confirmation of eradication with 13C-urea test over a time period of one year.
Results: Out of 1548 gastroscopies where CLO (Campylobacter-like Organism test) was taken that were done over a time period of 1 year, 242 (15.63%) patients had their helicobacter-like organism test positive. Triple regime was prescribed for eradication in all of them and retesting with 13C urea breath test after six weeks reveal successful eradication in 192 (79.3%) and failed eradication in only 50 (20.7%) of the patients.
Conclusion: The first line regime for the eradication of Helicobacter pylori used in our hospital is efficient for the eradication and there is no any amendment that has to be made in the current regime.